Harris Asaf, Al Mushref Mazen
Spectrum Health/Michigan State University Internal Medicine, Grand Rapids, Michigan.
Spectrum Health Medical Group Diabetes and Endocrinology, Grand Rapids, Michigan.
AACE Clin Case Rep. 2021 Jan-Feb;7(1):14-16. doi: 10.1016/j.aace.2020.12.005. Epub 2020 Dec 28.
Graves' disease is an autoimmune thyroid disease that is thought to develop following environmental exposure in patients with genetic predisposition. Our objective is to present the first report of Graves' disease onset immediately following recovery from mild coronavirus disease 2019 (COVID-19), a close temporal occurrence that should be studied further.
We describe the clinical course and laboratory features, including thyroid function studies, antibody testing, and polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2.
A 21-year-old woman with prediabetes, obesity, asthma, and gastroesophageal reflux disease presented to the emergency department reporting 3 days of tachycardia, palpitations, anxiety, and shortness of breath. Laboratory investigation revealed a thyroid-stimulating hormone level of 0.01 (0.30-5.00) mcIU/mL with a free thyroxine level of 3.8 (0.6-1.6) ng/dL, prompting endocrinology consultation. On physical examination, she had mild diffuse thyromegaly without tenderness and a history, which included hypothyroidism in her mother. Antibody testing results demonstrated thyroid-stimulating immunoglobulin and thyrotropin receptor antibody levels of 2.6 (<1.3) thyroid-stimulating immunoglobulin index and 17 (0.00-1.75) IU/L, respectively. Sixteen days before presenting to the ED, she was diagnosed with COVID-19 by polymerase chain reaction test after reporting typical symptoms, including fever. Infectious symptoms resolved within 10 days. She achieved clinical and laboratory improvements with a combination of methimazole and beta blocker therapy.
This case documents the occurrence of Graves' thyrotoxicosis following mild symptomatic COVID-19. Whether the preceding infection is coincidental or contributed to GD development requires definitive studies. This presentation may align with the theory of a viral link in the development of autoimmune thyroid disease in those with genetic predisposition.
格雷夫斯病是一种自身免疫性甲状腺疾病,被认为是在具有遗传易感性的患者接触环境因素后发病。我们的目的是首次报告在轻度冠状病毒病2019(COVID-19)康复后立即发生的格雷夫斯病,这种紧密的时间关联应进一步研究。
我们描述了临床过程和实验室特征,包括甲状腺功能检查、抗体检测以及严重急性呼吸综合征冠状病毒2的聚合酶链反应检测。
一名患有糖尿病前期、肥胖、哮喘和胃食管反流病的21岁女性因出现3天的心动过速、心悸、焦虑和呼吸急促前往急诊科就诊。实验室检查显示促甲状腺激素水平为0.01(0.30 - 5.00)mIU/mL,游离甲状腺素水平为3.8(0.6 - 1.6)ng/dL,促使进行内分泌会诊。体格检查时,她有轻度弥漫性甲状腺肿大,无压痛,其家族史包括母亲患有甲状腺功能减退症。抗体检测结果显示促甲状腺素受体抗体水平分别为2.6(<1.3)促甲状腺素受体抗体指数和17(0.00 - 1.75)IU/L。在前往急诊科就诊的16天前,她在报告包括发热在内的典型症状后通过聚合酶链反应检测被诊断为COVID-19。感染症状在10天内消退。她通过甲巯咪唑和β受体阻滞剂联合治疗实现了临床和实验室指标的改善。
本病例记录了轻度症状性COVID-19后发生格雷夫斯甲状腺毒症的情况。先前的感染是巧合还是促成了格雷夫斯病的发生需要确定性研究。这种表现可能与具有遗传易感性的个体自身免疫性甲状腺疾病发展中的病毒联系理论相符。